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 Tubulointerstitial fibrosis is by far one of the most 
common pathological hallmarks associated with 
cyclosporine (CsA) induced nephrotoxicity. Here we map 
the effects of altered microRNA (miR) expression levels on 
the TGFβ pathway in response to CsA treatment. Based on 
literature reviewed and the microarray data gathered by 
Gooch et al (publication in progress), we hypothesize that 
CsA alters the expression of renal miRs and that the altered 
expression of the miRs has implications in renal fibrosis that 
can be mapped out through the use of both in vivo and in 
vitro models. We predict that HEK 293 cells can be used as 
an in vitro model for comparison to the microarray data 
obtained by Gooch et al. We hope to show through parallel 
experiments, in mice renal tissue and HEK 293 cells, the 
usefulness of HEK 293 cells as an in vitro tool for the study 
of CsA-induced renal fibrosis.  
Through the use of q-rtPCR, we first validated the results 
obtained in a microarray study which demonstrated that 
certain miRs exhibit altered expression in response to CsA 
treatment in kidney tissues isolated from mice. Next, we 
looked at the use of HEK 293 cells as a proposed model for 
in vitro study of CsA regulated miRs in renal fibrosis. 
Finally we map changes in mRNA levels for some projected 
targets of the miRs shown to control various aspects of the 
TGFβ pathway. This complete work provides new insights 
into the involvement of miRs as regulators of the TGFβ 
pathway as well as demonstrates the usefulness of HEK 293 
cells as an in vitro model that can be used for further study 
of CsA induced renal fibrosis. 
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 The methods utilized for this project included cell culture 
of HEK 293 cells, treatment of the cell cultures with CsA, 
harvesting of total RNA from archived mice renal tissue as well 
as from the CsA treated HEK 293 cells. MTT viability assays 
were conducted to determine the LD50 for CsA on the HEK 293 
cell cultures, and q-rtPCR was used to evaluate the expression 
of renal miRs and mRNAs in both control and CsA treated 
groups. The ΔΔCT method was used to analyze the q-rtPCR 
results and statistical significance was calculated through the 
use of T Test and post Hoc ANOVA. 
Hypothesis: 
  
 CsA treatment leads to alterations in miR 
 expression levels and, subsequently, changes in 
 mRNAs that lead to the process of renal fibrosis. 
 
Goal 1: Validation of microarray 
 
Specific Aim 1: Validation of microarray data obtained 
by Gooch et al. showing the alterations in miR 
expression in mouse renal tissue 
 
Goal 2: Show usefulness of HEK 293 cells an in vitro 
model of  renal fibrosis 
 
Specific Aim 2: Show parallel changes in miRs 
between in vitro and in vivo models   
 
Specific Aim 3: Show parallel changes in mRNA in in 
vivo and in vitro models 
 
 Tubulointerstitial fibrosis is one of the most common 
pathological hallmarks of chronic kidney disease and many 
other end stage renal diseases. Fibrosis as a result of drug 
treatment programs like the administration of CsA to organ 
transplant recipients is of special to our team because there are 
certain considerations we can take into account for its cause, 
specifically the role of microRNAs in the progression of the 
disease state [1,2]. CsA is an immunosuppressant which works 
by inhibiting the dephosphorylation of cytosolic NFAT in the T 
cell preventing an immune response from occurring [3]. At the 
same time CsA also works to increase the levels of active 
TGFβ inside the cell, this action is what leads to the fibrotic 
effect seen in CsA patients [4]. TGFβ is involved in the 
production of ECM components, and an increase in its activity 
is directly related to renal fibrosis [4-7]. The TGFβ pathway has 
effects on numerous mRNAs and these alterations are believed 
to be a major cause of the fibrotic process [8-11]. One of the 
ways in which TGFβ may cause these alterations is through the 
involvement of microRNAs (miRs). miRs work by regulating the 
rate of transcription and translation of mRNAs and proteins. 
Our belief is that in response to CsA treatment the level of miR 
expression becomes altered, and this change in miR 
expression plays a vital role into the regulation of CsA induced 
renal fibrosis through modulation of the TGFβ pathway. Herein 
we show both in vivo (mice renal tissues) and in vitro models 
(HEK 293 cells) of miR alteration and mRNA changes involved 
in CsA treatment and CsA induced renal fibrosis.   
References 
 Through conducting the study we were able to validate the microarray findings for miR 21 
and miR 186 in the mice renal tissues. We conclude from this information the both of these miRs 
are most likely upregulated in response to CsA treatment. For miR 709 our in vivo findings appear 
to contradict the array data and more study needs to be preformed to look at this specific miR. The 
mRNAs in the in vivo model show no significant regulation. In the in vitro HEK 293 cell model none 
of the miRs examined had any significant amount of regulation. The in vitro mRNA study did show 
a significant amount of up regulation for all mRNAs examined in response to CsA treatment. In the 
time response experiment for the miRs we discovered that there appears to be an initial increase 
in miR expression for miRs 21 and 186, and that expression decreases with time. miR 709 had no 
significant time response in expression.  
 The findings of this work help to validate the 
microarray data previously obtained by our lab, as well 
as show the usefulness of the HEK 293 cell as an in vitro 
model in the study of CsA induced renal fibrosis. Based 
on the information gathered in this study we conclude 
that is is worthwhile to continue looking at the role miRs 
play in CsA induced renal fibrosis, and plan to continue 
to examine the HEK 293 cell as an in vitro model for this 
purpose. The information gathered herein helps to 
expand the knowledge of miR regulation on mRNAs and 
helps to grow the limited amount of knowledge on miR 
involvement in the fibrotic process. Based on this study 
we plan to examine more miRs and mRNAs and 
eventually plan to use miR mimics and anti-miR 
technology to gather a fuller understanding of miRs in 
the process of renal fibrosis. Doing this would contribute 
to our overall goal of developing a pharmaceutical agent 
of some from that could be administered to patients 
receiving CsA to prevent fibrosis from occurring without 
altering the immunosuppressive activity of the drug.    
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